March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Intravitreal Ranibizumab an Adjunct for Ahmed Valve Surgery in Open Angle Glaucoma: A Pilot Study
Author Affiliations & Notes
  • Rajen U. Desai
    Ophthalmology, Northwestern University, Chicago, Illinois
    Ophthalmology, Univ of California - SF, San Francisco, California
  • Kuldev Singh
    Ophthalmology, Stanford University, Palo Alto, California
  • Shan C. Lin
    Ophthalmology, Univ of California - SF, San Francisco, California
  • Footnotes
    Commercial Relationships  Rajen U. Desai, None; Kuldev Singh, Alcon, Transcend, Ivantis (C); Shan C. Lin, Genentech (F)
  • Footnotes
    Support  Genentech, Inc.
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 3746. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Rajen U. Desai, Kuldev Singh, Shan C. Lin; Intravitreal Ranibizumab an Adjunct for Ahmed Valve Surgery in Open Angle Glaucoma: A Pilot Study. Invest. Ophthalmol. Vis. Sci. 2012;53(14):3746.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To determine the safety and efficacy of intravitreal ranibizumab therapy before and after Ahmed tube insertion for open angle glaucoma (OAG) as a means of achieving better postoperative intraocular pressure (IOP) control.

Methods: : Open angle glaucoma patients scheduled for Ahmed valve surgery, with or without combined phacoemulsification cataract surgery, were randomized to either ranibizumab or control groups. Ranibizumab (0.5 mg in 0.05 ml) was administered intravitreally at 3 time points: 9 days prior to surgery, 1 month post-surgery, and 2 months post-surgery. Patients in the control group underwent the same procedure without ranibizumab. Success at 6 months postoperatively was defined as IOP < 18 mmHg with no adjunctive medications, or IOP < 15 mmHg with one adjunctive medication.

Results: : The study and control arms included 6 and 5 subjects, respectively, with 4 in each arm undergoing combined cataract surgery. In the ranibizumab arm, the pre- and postoperative IOP/medication usage was 21.0 ± 6.7 mmHg on 3.2 ± 1.5 medications and 14.7 ± 1.9 mmHg on 0.5 ± 0.8 medications, respectively. In the control arm, the pre- and postoperative IOP/medication usage was 18.8 ± 3.8 mmHg on 2.8 ± 1.3 medications and 16.2 ± 3.6 mmHg with 1.8 ± 1.6 medications, respectively. Success was achieved in 83% of subjects in the ranibizumab group compared to 40% in the control group (2-tailed Fisher’s exact test, p = 0.24).

Conclusions: : The findings from this small pilot comparative study suggest that intravitreal ranibizumab use may be a safe and potentially effective adjunctive treatment modality in improving success after Ahmed tube placement.

Keywords: wound healing • vascular endothelial growth factor • intraocular pressure 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×